Real World Comparison of Asciminib Versus Ponatinib in Chronic Myeloid Leukemia with Propensity Score-Matched Analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Chronic myeloid leukemia (CML) has an excellent prognosis with tyrosine kinase inhibitors (TKIs); however, approximately 40-50% of patients discontinue at least one TKI because of resistance or intolerance. While Ponatinib (PON) is highly effective against resistant disease, Asciminib (ASC) offers robust efficacy with favorable tolerability profile. In the absence of randomized head-to-head trials, we compared outcomes of ASC versus PON using propensity score-matched (PSM) analysis. We conducted a real-world analysis of 762 CML patients previously treated with ≥1 TKI (ASC, n=451; PON, n=311), from an international multicenter cohort. PSM generated 139 balanced pairs after adjusting for age, prior TKI exposure, cardiovascular history, ABL kinase domain mutations, and reason for prior TKI failure. The primary endpoints, evaluated in the matched cohort, were 12-month failure-free survival (FFS) and event-free survival (EFS). ASC was associated with similar molecular response rates and FFS to PON, while EFS was significantly longer with ASC, likely reflecting its more favorable tolerability and lower rate of discontinuation due to intolerance. The difference in EFS was particularly pronounced among patients treated for prior TKI intolerance and in lower-risk subgroups. A sensitivity analysis restricted to patients naïve to both agents (117 matched pairs) confirmed the EFS difference (12-month EFS, 88.6% vs 73.2%; HR 2.48; p=0.002). ASC was associated with similar molecular response and FFS outcomes to PON These findings suggest that ASC was associated with similar real-world molecular response and FFS outcomes to PON, while EFS was longer with ASC, largely driven by differences in treatment discontinuation related to intolerance. ASC may represent an attractive option for patients with prior TKI intolerance, while PON remains an important treatment option for patients with resistant disease.
Source: Blood Advances
Authors: Maria Agustina Perusini, Camille Kockerols, Franck Emmanuel Nicolini, Daniela Zackova, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Lynn Lynn Savoie, Christophe Bouvier, Petra Čičátková, Hana Klamova, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Tomoiku Takaku, Hiroshi Ureshino, Shinya Kimura, Sung-Eun Lee, Valentín Garcia-Gutierrez, Jiri Mayer, Dragana Milojkovic, Andrew J. Innes, Simone Claudiani, Hassan Sibai, Jane F Apperley, Peter E. Westerweel, Dennis Dong Hwan Kim
Institutions: University of Toronto, Erasmus MC, Inserm, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, University Hospital Brno, University of Bologna, Fundación para la Investigación, Docencia y Prevención del Cáncer, Sapienza University of Rome, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, University of Turin, University of Calgary, Arthur J.E. Child Comprehensive Cancer Centre, Institute of Haematology and Blood Transfusion, Princess Margaret Cancer Centre, Saitama Medical University, Hiroshima University, Saga University, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Hospital Universitario Ramón y Cajal, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Imperial College London, Albert Schweitzer Ziekenhuis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7236383279
